TABLE OF CONTENTS
1 INTRODUCTION 40
1.1 OBJECTIVES OF THE STUDY 40
1.2 MARKET DEFINITION 40
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICAIN-VITRO TOXICOLOGY TESTING MARKET 40
1.4 CURRENCY AND PRICING 42
1.5 LIMITATIONS 42
1.6 MARKETS COVERED 42
2 MARKET SEGMENTATION 45
2.1 MARKETS COVERED 45
2.2 GEOGRAPHICAL SCOPE 46
2.3 YEARS CONSIDERED FOR THE STUDY 47
2.4 DBMR TRIPOD DATA VALIDATION MODEL 48
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 51
2.6 MULTIVARIATE MODELLING 52
2.7 PRODUCT AND SERVICE SEGMENT LIFELINE CURVE 52
2.8 MARKET END USER COVERAGE GRID 53
2.9 DBMR MARKET POSITION GRID 54
2.10 VENDOR SHARE ANALYSIS 55
2.11 SECONDARY SOURCES 56
2.12 ASSUMPTIONS 56
3 EXECUTIVE SUMMARY 57
4 PREMIUM INSIGHTS 60
4.1 PESTEL ANALYSIS 61
4.2 PORTERS ANALYSIS 62
5 MIDDLE EAST & AFRICAIN-VITRO TOXICOLOGY TESTING MARKET, INDUSTRY INSIGHTS 63
6 MIDDLE EAST & AFRICAIN-VITRO TOXICOLOGY TESTING MARKET, REGULATIONS 65
7 MARKET OVERVIEW 68
7.1 DRIVERS 70
7.1.1 INCREASING DEMAND FOR TOXICOLOGY TESTING PRODUCTS 70
7.1.2 RAPIDLY GROWING PHARMACEUTICAL AND MEDICAL DEVICE INDUSTRIES 70
7.1.3 RISING INVESTMENT IN R&D BY KEY MARKET PLAYERS 71
7.1.4 TECHNOLOGICAL ADVANCEMENTS TO DEVELOP NEW TOXICOLOGY TESTING METHODS 71
7.2 RESTRAINTS 72
7.2.1 HIGH COSTS ASSOCIATED WITH IN-VITRO TOXICOLOGY TESTING AND PRODUCTS 72
7.2.2 COMPLEXITY OF BIOLOGICAL SYSTEMS 72
7.2.3 NEED FOR SKILLED PERSONNEL AND INFRASTRUCTURE 73
7.3 OPPORTUNITIES 73
7.3.1 GROWING ADOPTION OF QUALITY CHECK PRODUCTS TO PREVENT PRODUCT RECALLS 73
7.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS FOR MARKET EXPANSION 74
7.3.3 GROWING DEMAND FOR PERSONALIZED MEDICINE AND PRECISION TOXICOLOGY 74
7.4 CHALLENGES 75
7.4.1 ETHICAL AND PUBLIC PERCEPTION 75
7.4.2 REGULATORY ACCEPTANCE AND ENDORSEMENT OF IN-VITRO TESTING METHODS 75
8 MIDDLE EAST & AFRICAIN-VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT AND SERVICE 76
8.1 OVERVIEW 77
8.2 CONSUMABLES 80
8.3 SERVICES 81
8.3.1 CYTOTOXICITY 82
8.3.2 GENE TOXICITY 82
8.3.3 HEPATOTOXICITY 82
8.3.4 OPHTHALMIC TOXICITY 82
8.3.5 CARDIOTOXICITY 82
8.3.6 NEPHROTOXICITY 82
8.3.7 NEUROTOXICITY 83
8.3.8 OTHERS 83
8.4 ASSAYS 83
8.4.1 CELL-BASED ELISA & WESTERN BLOTS 84
8.4.2 ENZYME TOXICITY ASSAYS 84
8.4.3 RECEPTOR-BINDING ASSAYS 84
8.4.4 BACTERIAL TOXICITY ASSAYS 84
8.4.5 TISSUE CULTURE ASSAYS 84
8.4.6 OTHER ASSAYS 84
8.5 EQUIPMENTS 85
8.6 SOFTWARE 86
9 MIDDLE EAST & AFRICAIN-VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT AND TEST 87
9.1 OVERVIEW 88
9.2 ADME (ABSORPTION, DISTRIBUTION, METABOLISM, & EXCRETION) TESTING 91
9.3 CYTOTOXICITY TESTING 92
9.4 GENOTOXICITY TESTING 93
9.5 DERMAL TOXICITY TESTING 94
9.6 OCULAR TOXICITY TESTING 95
9.7 ORGAN TOXICITY TESTING 96
9.8 SKIN IRRITATION, CORROSION, & SENSITIZATION TESTING 97
9.9 PHOTOTOXICITY TESTING 97
9.10 OTHER TOXICITY ENDPOINTS AND TESTS 98
10 MIDDLE EAST & AFRICAIN-VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY 100
10.1 OVERVIEW 101
10.2 CELL CULTURE TECHNOLOGIES 104
10.3 HIGH-THROUGHPUT TECHNOLOGIES 105
10.4 MOLECULAR IMAGING 106
10.5 OMICS TECHNOLOGY 107
11 MIDDLE EAST & AFRICAIN-VITRO TOXICOLOGY TESTING MARKET, BY METHOD 108
11.1 OVERVIEW 109
11.2 CELLULAR ASSAYS 111
11.3 BIOCHEMICAL ASSAYS 112
11.4 EX-VIVO MODELS 113
11.5 IN SILICO MODELS 114
12 MIDDLE EAST & AFRICAIN-VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY 116
12.1 OVERVIEW 117
12.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES 120
12.2.1 CONSUMABLES 121
12.2.2 SERVICES 121
12.2.3 ASSAYS 121
12.2.4 EQUIPMENTS 121
12.2.5 SOFTWARE 121
12.3 DIAGNOSTICS 121
12.3.1 CONSUMABLES 123
12.3.2 SERVICES 123
12.3.3 ASSAYS 123
12.3.4 EQUIPMENTS 123
12.3.5 SOFTWARE 123
12.4 FOOD 123
12.4.1 CONSUMABLES 124
12.4.2 SERVICE 124
12.4.3 ASSAYS 124
12.4.4 EQUIPMENTS 125
12.4.5 SOFTWARE 125
12.5 CHEMICALS 125
12.5.1 CONSUMABLES 126
12.5.2 SERVICES 126
12.5.3 ASSAYS 126
12.5.4 EQUIPMENTS 126
12.5.5 SOFTWARE 126
12.6 COSMETICS AND HOUSEHOLD PRODUCTS 127
12.6.1 CONSUMABLES 128
12.6.2 SERVICES 128
12.6.3 ASSAYS 128
12.6.4 EQUIPMENTS 128
12.6.5 SOFTWARE 128
13 MIDDLE EAST & AFRICAIN-VITRO TOXICOLOGY TESTING MARKET, BY DISTRIBUTION CHANNEL 129
13.1 OVERVIEW 130
13.2 DIRECT TENDER 132
13.3 RETAIL SALES 133
13.4 OTHERS 134
14 MIDDLE EAST & AFRICAIN-VITRO TOXICOLOGY TESTING MARKET, BY REGION 136
14.1 MIDDLE EAST AND AFRICA 137
14.1.1 SAUDI ARABIA 146
14.1.2 SOUTH AFRICA 151
14.1.3 U.A.E. 156
14.1.4 EGYPT 161
14.1.5 ISRAEL 166
14.1.6 REST OF MIDDLE EAST AND AFRICA 171
15 MIDDLE EAST & AFRICAIN-VITRO TOXICOLOGY TESTING MARKET, COMPANY LANDSCAPE 172
15.1 COMPANY SHARE ANALYSIS: GLOBAL 172
16 SWOT ANALYSIS 173
17 COMPANY PROFILE 174
17.1 THERMO FISHER SCIENTIFIC INC. 174
17.1.1 COMPANY SNAPSHOT 174
17.1.2 REVENUE ANALYSIS 174
17.1.3 COMPANY SHARE ANALYSIS 175
17.1.4 PRODUCT PORTFOLIO 175
17.1.5 RECENT DEVELOPMENT 175
17.2 LABCORP DRUG DEVELOPMENT 176
17.2.1 COMPANY SNAPSHOT 176
17.2.2 REVENUE ANALYSIS 176
17.2.3 COMPANY SHARE ANALYSIS 177
17.2.4 PRODUCT PORTFOLIO 177
17.2.5 RECENT DEVELOPMENT 177
17.3 MERCK KGAA 178
17.3.1 COMPANY SNAPSHOT 178
17.3.2 REVENUE ANALYSIS 178
17.3.3 COMPANY SHARE ANALYSIS 179
17.3.4 PRODUCT PORTFOLIO 179
17.3.5 RECENT DEVELOPMENT 179
17.4 CHARLES RIVER LABORATORIES. 180
17.4.1 COMPANY SNAPSHOT 180
17.4.2 REVENUE ANALYSIS 180
17.4.3 COMPANY SHARE ANALYSIS 181
17.4.4 PRODUCT PORTFOLIO 181
17.4.5 RECENT DEVELOPMENT 181
17.5 LONZA 182
17.5.1 COMPANY SNAPSHOT 182
17.5.2 REVENUE ANALYSIS 182
17.5.3 COMPANY SHARE ANALYSIS 183
17.5.4 PRODUCT PORTFOLIO 183
17.5.5 RECENT DEVELOPMENT 183
17.6 AAT BIOQUEST, INC. 184
17.6.1 COMPANY SNAPSHOT 184
17.6.2 PRODUCT PORTFOLIO 184
17.6.3 RECENT DEVELOPMENTS 184
17.7 ARAGEN LIFE SCIENCES LTD. 185
17.7.1 COMPANY SNAPSHOT 185
17.7.2 REVENUE ANALYSIS 185
17.7.3 PRODUCT PORTFOLIO 186
17.7.4 RECENT DEVELOPMENT 186
17.8 BIOIVT 187
17.8.1 COMPANY SNAPSHOT 187
17.8.2 PRODUCT PORTFOLIO 187
17.8.3 RECENT DEVELOPMENT 187
17.9 BIO-RAD LABORATORIES, INC. 188
17.9.1 COMPANY SNAPSHOT 188
17.9.2 REVENUE ANALYSIS 188
17.9.3 PRODUCT PORTFOLIO 189
17.9.4 RECENT DEVELOPMENT 189
17.10 CATALENT, INC 190
17.10.1 COMPANY SNAPSHOT 190
17.10.2 REVENUE ANALYSIS 190
17.10.3 PRODUCT PORTFOLIO 191
17.10.4 RECENT DEVELOPMENT 191
17.11 CREATIVE BIOARRAY. 192
17.11.1 COMPANY SNAPSHOT 192
17.11.2 PRODUCT PORTFOLIO 192
17.11.3 RECENT DEVELOPMENTS 192
17.12 CREATIVE BIOLABS. 193
17.12.1 COMPANY SNAPSHOT 193
17.12.2 PRODUCT PORTFOLIO 193
17.12.3 RECENT DEVELOPMENTS 193
17.13 CYPROTEX LIMITED 194
17.13.1 COMPANY SNAPSHOT 194
17.13.2 PRODUCT PORTFOLIO 194
17.13.3 RECENT DEVELOPMENT 194
17.14 EUROFINS SCIENTIFIC 195
17.14.1 COMPANY SNAPSHOT 195
17.14.2 REVENUE ANALYSIS 195
17.14.3 PRODUCT PORTFOLIO 196
17.14.4 RECENT DEVELOPMENT 196
17.15 GENTRONIX 197
17.15.1 COMPANY SNAPSHOT 197
17.15.2 PRODUCT PORTFOLIO 197
17.15.3 RECENT DEVELOPMENT 197
17.16 IONTOX 198
17.16.1 COMPANY SNAPSHOT 198
17.16.2 PRODUCT PORTFOLIO 198
17.16.3 RECENT DEVELOPMENT 198
17.17 INSPHERO. 199
17.17.1 COMPANY SNAPSHOT 199
17.17.2 PRODUCT PORTFOLIO 199
17.17.3 RECENT DEVELOPMENT 199
17.18 INTERTEK GROUP PLC 200
17.18.1 COMPANY SNAPSHOT 200
17.18.2 REVENUE ANALYSIS 200
17.18.3 PRODUCT PORTFOLIO 201
17.18.4 RECENT DEVELOPMENT 201
17.19 MB RESEARCH LABORATORIES 202
17.19.1 COMPANY SNAPSHOT 202
17.19.2 PRODUCT PORTFOLIO 202
17.19.3 RECENT DEVELOPMENTS 202
17.20 PREFERRED CELL SYSTEMS 203
17.20.1 COMPANY SNAPSHOT 203
17.20.2 PRODUCT PORTFOLIO 203
17.20.3 RECENT DEVELOPMENTS 203
17.21 PROMEGA CORPORATION 204
17.21.1 COMPANY SNAPSHOT 204
17.21.2 PRODUCT PORTFOLIO 204
17.21.3 RECENT DEVELOPMENTS 205
17.22 QIAGEN 206
17.22.1 COMPANY SNAPSHOT 206
17.22.2 REVENUE ANALYSIS 206
17.22.3 PRODUCT PORTFOLIO 207
17.22.4 RECENT DEVELOPMENTS 207
17.23 SGS SOCIT GNRALE DE SURVEILLANCE SA 208
17.23.1 COMPANY SNAPSHOT 208
17.23.2 REVENUE ANALYSIS 208
17.23.3 PRODUCT PORTFOLIO 209
17.23.4 RECENT DEVELOPMENTS 209
17.24 SHANGHAI MEDICILON INC. 210
17.24.1 COMPANY SNAPSHOT 210
17.24.2 REVENUE ANALYSIS 210
17.24.3 PRODUCT PORTFOLIO 211
17.24.4 RECENT DEVELOPMENT 211
18 QUESTIONNAIRE 212
19 RELATED REPORTS 215

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.